ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: FR-PO416

Body Mass Index as a Risk Factor for Kidney Health in Childhood Cancer Survivors

Session Information

  • Pediatric Nephrology - I
    November 04, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
    Abstract Time: 10:00 AM - 12:00 PM

Category: Pediatric Nephrology

  • 1800 Pediatric Nephrology

Authors

  • Chui, Hayton, The Hospital for Sick Children, Toronto, Ontario, Canada
  • Jain, Anshika, The Hospital for Sick Children, Toronto, Ontario, Canada
  • Nunes, Sophia, The Hospital for Sick Children, Toronto, Ontario, Canada
  • Farma, Simrandeep, The Hospital for Sick Children, Toronto, Ontario, Canada
  • Zappitelli, Michael, The Hospital for Sick Children, Toronto, Ontario, Canada

Group or Team Name

  • The first and second authors contributed equally to this work.
Background

Childhood Cancer (CC) survivors are at risk for kidney outcomes(KO). High Body Mass Index (BMI) is a risk factor for kidney disease. We evaluated the relation between BMI in CC therapy with KO.

Methods

Secondary use of national prospective data(Cancer in Young People in Canada database: ≤15-yrs-old diagnosed with cancer at 17 Canadian centers after Jan 1, 2001; followed up to 6 yrs). Excluded: no birth date/sex; died during therapy; no BMI. Exposures: first BMI(within 6 mths of diagnosis); last BMI; last vs. first percent change BMI percentile. Outcomes: any kidney or BP outcome after CC therapy. Multivariate logistic regression used to evaluate exposure-KO relations, adjusted for location, cancer diagnosis, graft vs. host and number of hematopoietic transplants.

Results

9805 children included; n=90(0.92%) had KO recorded. Patients with vs. without KO had higher first BMI, lower last BMI and BMI %change (only significant for first BMI, Fig 1). Adjusted analyses: first BMI was associated with higher adjusted odds for post-therapy KO(adjusted OR 1.01 [1.00-1.02], p<0.02, Table 1).

Conclusion

Higher adiposity early in CC therapy is associated with kidney and BP conditions. It is unclear if this is due to higher risk of recurrent AKI or underlying long-term risk. Children with high BMI at CC therapy start may be targeted for closer kidney health follow-up post-therapy.